Gilead Sciences

Coalition of Leading U.S. Companies Reveals Joint Progress to Combat HIV Epidemic on Eve of World AIDS Day

Retrieved on: 
Thursday, November 30, 2023

Washington, D.C., Nov. 30, 2023 (GLOBE NEWSWIRE) -- As Congress debates potential deep cuts to federal funding for critical HIV programs on the eve of World AIDS Day, a growing number of leading private sector companies are stepping up to accelerate progress to end America’s ongoing HIV epidemic.

Key Points: 
  • Washington, D.C., Nov. 30, 2023 (GLOBE NEWSWIRE) -- As Congress debates potential deep cuts to federal funding for critical HIV programs on the eve of World AIDS Day, a growing number of leading private sector companies are stepping up to accelerate progress to end America’s ongoing HIV epidemic.
  • Forty businesses, anchored by several major employers and brands, have joined forces as part of U.S. Business Action to End HIV , a coalition of companies committed to ending the HIV epidemic in the U.S.
  • We are honored to do our part,” said Kevin Host, Senior Vice President of Pharmacy Operations at Walmart.
  • Over 1.2 million people in the United States are living with HIV, with nearly 35,000 new infections each year.

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Retrieved on: 
Monday, November 20, 2023

HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.

Key Points: 
  • HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.
  • The analyses published were conducted with a simian immunodeficiency virus (SIV) model, commonly used in a preclinical setting as a surrogate to HIV.
  • One vector is based on lymphocytic choriomeningitis virus (LCMV) as its arenaviral backbone; another vector is based on Pichinde virus (PICV).
  • HB-500 is one of two separate development programs in HOOKIPA’s collaboration and license agreement with Gilead.

USA Solid Tumor Therapeutics Market Outlook to 2028 - Field of Oncology is Moving Towards more Personalized Treatment - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 26, 2023

The "USA Solid Tumor Therapeutics Market Outlook to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "USA Solid Tumor Therapeutics Market Outlook to 2028" report has been added to ResearchAndMarkets.com's offering.
  • United States holds a significant share in the solid tumor therapeutics market.
  • Solid tumors are a significant healthcare concern in the United States, contributing to a significant portion of cancer cases & mortality.
  • The field of oncology is moving towards more personalized treatment approaches, where therapies are tailored to an individual patient's genetic & molecular profile.

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

Retrieved on: 
Tuesday, December 19, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231218814564/en/
    Compugen utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies.
  • Gilead will make Compugen an upfront payment of $60 million and $30 million in a near term milestone payment subject to IND clearance of COM503 expected in 2024.
  • Compugen will also be eligible to receive single-digit to low double-digit tiered royalties on worldwide net sales.
  • This transaction with Compugen is expected to reduce Gilead’s GAAP and non-GAAP 2023 EPS by approximately $0.03 - $0.05.

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

Retrieved on: 
Monday, November 13, 2023

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Helen Collins, MD, to its board of directors.

Key Points: 
  • NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Helen Collins, MD, to its board of directors.
  • Dr. Collins is an industry veteran with significant experience in oncology/hematology drug development and will serve on the Research and Development Committee of the Board.
  • “We are pleased to welcome Helen, an accomplished healthcare executive with extensive drug development and corporate strategy experience, to our Board of Directors,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech.
  • Dr. Collins currently serves on the board of directors for Kura Oncology.

Electra Therapeutics Appoints Kathy Dong, PharmD, MBA, as President and Chief Executive Officer

Retrieved on: 
Monday, December 11, 2023

Electra Therapeutics, Inc. , a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced the appointment of Kathy Dong, PharmD, MBA, as President and Chief Executive Officer.

Key Points: 
  • Electra Therapeutics, Inc. , a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced the appointment of Kathy Dong, PharmD, MBA, as President and Chief Executive Officer.
  • View the full release here: https://www.businesswire.com/news/home/20231211224486/en/
    Electra President and CEO Kathy Dong PharmD, MBA (Photo: Business Wire)
    “We are excited to have Kathy take on the role of CEO of Electra.
  • Dr. Rosenthal will continue to serve as a member of Electra’s board of directors and as Chief Executive Officer of Star Therapeutics, the company that spun out Electra.
  • Previously, she was Chief Operating Officer of Star Therapeutics since 2019, where she held strategic and operational responsibilities across the Star portfolio, including building Electra Therapeutics and Vega Therapeutics from discovery stage into the clinic.

Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year

Retrieved on: 
Monday, December 11, 2023

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World) for the third consecutive year.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World) for the third consecutive year.
  • The company was also included on the Dow Jones Sustainability North America Index (DJSI North America).
  • These rankings are based on an in-depth analysis of Gilead’s sustainability performance and highlight the company’s longstanding sustainable business practices and transparency on environmental, social and governance (ESG) issues.
  • “We are very pleased that Gilead’s commitment to corporate responsibility is recognized once again with inclusion on the Dow Jones Sustainability World Index,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences.

Avoro Ventures Adds Mark Chin as a Partner

Retrieved on: 
Friday, December 1, 2023

Avoro Ventures, a global venture capital firm investing in life sciences, announced today that Mark Chin has joined the firm as a Partner, focused on its venture capital investment efforts.

Key Points: 
  • Avoro Ventures, a global venture capital firm investing in life sciences, announced today that Mark Chin has joined the firm as a Partner, focused on its venture capital investment efforts.
  • Mark has 15 years of healthcare experience across venture capital, strategy consulting, business and corporate development.
  • Prior to joining Avoro Ventures, Mark was a Managing Director at Arix Bioscience focused on private and public biotech investments.
  • Mark will be joining Uya Chuluunbaatar, PhD, as an Investment Partner working with Behzad Aghazadeh, PhD, Managing Partner of Avoro Ventures, and Garheng Kong, MD/PhD, Avoro Ventures Advisory Partner.

AWS Announces Amazon Q to Reimagine the Future of Work

Retrieved on: 
Tuesday, November 28, 2023

Amazon Q is available to customers in preview, with Amazon Q in Connect generally available and Amazon Q in AWS Supply Chain coming soon.

Key Points: 
  • Amazon Q is available to customers in preview, with Amazon Q in Connect generally available and Amazon Q in AWS Supply Chain coming soon.
  • That is why AWS created Amazon Q, helping customers unlock the full benefit of generative AI for every employee.
  • Trained on 17 years of AWS knowledge and experience, Amazon Q transforms the way developers and IT professionals build, deploy, and operate applications and workloads on AWS.
  • To troubleshoot an issue like an EC2 or Amazon Simple Storage Service (Amazon S3) configuration error, customers simply press the “Troubleshoot with Amazon Q” button while in the AWS Management Console to have Amazon Q research the error and suggest a fix.

AHF Protests ‘Greedy Gilead’ for Price Gouging

Retrieved on: 
Wednesday, November 29, 2023

On Wednesday, November 29th, AIDS Healthcare Foundation (AHF) advocates will rally at Lotte New York Palace in protest of Gilead Sciences ’ ongoing efforts to rack up exorbitant profits while restricting access to lifesaving medications.

Key Points: 
  • On Wednesday, November 29th, AIDS Healthcare Foundation (AHF) advocates will rally at Lotte New York Palace in protest of Gilead Sciences ’ ongoing efforts to rack up exorbitant profits while restricting access to lifesaving medications.
  • This press release features multimedia.
  • Since 2021, AHF has been taking on Gilead Sciences and CEO Daniel O’Day, holding more than two dozen protests in multiple cities, including Washington, DC; Miami, FL; Boston, MA; and Foster City, CA at the drugmaker’s corporate headquarters.
  • AHF also has published full page ads in the San Francisco Chronicle and the Daily Record in New Jersey near Gilead’s new East Coast facilities, as well as posted online at Gilead.org .